17471-43-1Relevant articles and documents
-
Adams,B.L.,Kovacic,P.
, p. 1310 - 1311 (1972)
-
Intramolecular C-H Amination Reaction Provides Direct Access to 1,2-Disubstituted Diamondoids
Hrdina, Radim,Metz, Fabian M.,Larrosa, Marta,Berndt, Jan-Philipp,Zhygadlo, Yevgeniya Y.,Becker, Sabine,Becker, Jonathan
, p. 6231 - 6236 (2015)
We present a new approach to disubstituted diamondoids from corresponding carboxylic acids. A dirhodium-acetate-catalyzed (1 mol-%) nitrene insertion reaction of sulfamides was, for the first time, applied to intramolecular C-H functionalization reactions of rigid tricyclic frameworks. This straightforward approach enables the effective and regioselective synthesis of a variety of diamondoid-based cyclic sulfamidates, which are synthetically valuable building blocks. Reductive deprotection of the sulfamidate moiety leads to corresponding 1,3-amino alcohol derivatives. Oxidation of the sulfamidate moiety by KMnO4 provides access to 1,3-keto alcohols or imines. Finally, we report the synthesis of Vildagliptin analogues as new antidiabetic drug candidates (DPP-4 inhibitors). Intramolecular dirhodium-acetate-catalyzed (1 mol-%) nitrene insertion reactions provide direct access to 1,2-disubstituted diamondoids. This approach was applied to the synthesis of Vildagliptin (DPP-4 inhibitor) analogues.
-Rearrangement of iminium salts provides access to heterocycles with adamantane scaffold
Becker, Jonathan,Duman, Ediz,Hausmann, Heike,Hrdina, Radim,Zonker, Benjamin
, p. 4941 - 4945 (2020)
We describe a Br?nsted acid-catalysed cascade reaction consisting of a Wagner-Meerwein rearrangement and a subsequent intra- or intermolecular Friedel-Crafts reaction leading to adamantane-based heterocycles. In contrast to the reported W.-M. rearrangements, in this case an iminium moiety serves as the acceptor of a migrating nucleophilic alkyl group in a [1,2]-alkyl shift. This journal is
Discovery of adamantane based highly potent HDAC inhibitors
Gopalan, Balasubramanian,Ponpandian, Thanasekaran,Kachhadia, Virendra,Bharathimohan, Kuppusamy,Vignesh, Radhakrishnan,Sivasudar, Velaiah,Narayanan, Shridhar,Mandar, Bhonde,Praveen, Rajendran,Saranya, Nithyanandan,Rajagopal, Sriram,Rajagopal, Sridharan
, p. 2532 - 2537 (2013/06/27)
Herein, we report the development of highly potent HDAC inhibitors for the treatment of cancer. A series of adamantane and nor-adamantane based HDAC inhibitors were designed, synthesized and screened for the inhibitory activity of HDAC. A number of compounds exhibited GI50 of 10-100 nM in human HCT116, NCI-H460 and U251 cancer cells, in vitro. Compound 32 displays efficacy in human tumour animal xenograft model.